Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism. IDH mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Lang, Fengchao, Chou, Fu-Ju, Zaghloul, Kareem A., Yang, Chunzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554955/
https://www.ncbi.nlm.nih.gov/pubmed/32825279
http://dx.doi.org/10.3390/biomedicines8090294
_version_ 1783593894602080256
author Liu, Yang
Lang, Fengchao
Chou, Fu-Ju
Zaghloul, Kareem A.
Yang, Chunzhang
author_facet Liu, Yang
Lang, Fengchao
Chou, Fu-Ju
Zaghloul, Kareem A.
Yang, Chunzhang
author_sort Liu, Yang
collection PubMed
description Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism. IDH mutation establishes distinctive patterns in metabolism, cancer biology, and the therapeutic sensitivity of glioma. Thus, a deeper understanding of the roles of IDH mutations is of great value to improve the therapeutic efficacy of glioma and other malignancies that share similar genetic characteristics. In this review, we focused on the genetics, biochemistry, and clinical impacts of IDH mutations in glioma.
format Online
Article
Text
id pubmed-7554955
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75549552020-10-14 Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications Liu, Yang Lang, Fengchao Chou, Fu-Ju Zaghloul, Kareem A. Yang, Chunzhang Biomedicines Review Mutations in isocitrate dehydrogenase (IDH) are commonly observed in lower-grade glioma and secondary glioblastomas. IDH mutants confer a neomorphic enzyme activity that converts α-ketoglutarate to an oncometabolite D-2-hydroxyglutarate, which impacts cellular epigenetics and metabolism. IDH mutation establishes distinctive patterns in metabolism, cancer biology, and the therapeutic sensitivity of glioma. Thus, a deeper understanding of the roles of IDH mutations is of great value to improve the therapeutic efficacy of glioma and other malignancies that share similar genetic characteristics. In this review, we focused on the genetics, biochemistry, and clinical impacts of IDH mutations in glioma. MDPI 2020-08-20 /pmc/articles/PMC7554955/ /pubmed/32825279 http://dx.doi.org/10.3390/biomedicines8090294 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Yang
Lang, Fengchao
Chou, Fu-Ju
Zaghloul, Kareem A.
Yang, Chunzhang
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title_full Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title_fullStr Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title_full_unstemmed Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title_short Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
title_sort isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554955/
https://www.ncbi.nlm.nih.gov/pubmed/32825279
http://dx.doi.org/10.3390/biomedicines8090294
work_keys_str_mv AT liuyang isocitratedehydrogenasemutationsingliomageneticsbiochemistryandclinicalindications
AT langfengchao isocitratedehydrogenasemutationsingliomageneticsbiochemistryandclinicalindications
AT choufuju isocitratedehydrogenasemutationsingliomageneticsbiochemistryandclinicalindications
AT zaghloulkareema isocitratedehydrogenasemutationsingliomageneticsbiochemistryandclinicalindications
AT yangchunzhang isocitratedehydrogenasemutationsingliomageneticsbiochemistryandclinicalindications

Ejemplares similares